The influence of ethnicity on disease outcome in patients with chronic hepatitis B infection

Özgür M. Koc1,2,3,4 | Geert Robaeys3,4,5 | Beytullah Yildirim6 | Dirk Posthouwer1 | Niel Hens7,8 | Ger H. Koek2,9,10

Since the cultural diversity in Western Europe is growing, this study assessed whether foreign-born chronic hepatitis B (CHB) patients have more cirrhosis than Dutch- or Belgian-born patients, with a main focus on the Turkish population. Baseline characteristics (eg, socioeconomic status [SES]), biological characteristics, and disease outcome (eg, cirrhosis) were collected for all patients. Between December 2009 and January 2015, 269 CHB patients participated from the outpatient departments of three hospitals in the Netherlands, Belgium, and Turkey. Out of the 269 CHB patients, 210 were foreign-born and 59 were Dutch- or Belgian-born. Compared with Dutch- or Belgian-born patients, foreign-born patients had a higher prevalence of low SES (58% vs 31%; P = 0.001) and cirrhosis (27% vs 10%; P = 0.007). Among the Turkish population, there were no significant differences regarding the prevalence of low SES (73% vs 61%; P = 0.170), alcohol abuse (1% vs 5%; P = 0.120), anti-hepatitis C virus positivity (4% vs 0%; P = 0.344), anti-hepatitis D virus positivity (1% vs 6%; P = 0.297), and cirrhosis (37% vs 27%; P = 0.262) between patients (n = 102) living in Turkey (local) and Turkish CHB (n = 38) patients living in the Netherlands or Belgium (immigrant). In multivariate analysis, low SES (odds ratio, 5.7; 95% confidence interval, 2.3-14.5; P < 0.001) was associated with cirrhosis. In this study, foreign-born CHB patients were associated with more advanced HBV-related liver disease with 27% having cirrhosis. However, ethnicity was not associated with cirrhosis when SES was included in the multivariate analysis. The similar prevalence of cirrhosis in local Turkish compared to immigrant Turkish CHB patients is novel and warrants further investigation.

KEYWORDS
cirrhosis, disease outcome, ethnicity, hepatitis B, socioeconomic status, Turkish

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2018 The Authors. Journal of Medical Virology Published by Wiley Periodicals, Inc.
1 | INTRODUCTION

Hepatitis B virus (HBV) infection is one of the major infectious diseases with an estimated two billion people infected with HBV worldwide and more than 240 million chronically infected in the year 2016. An estimated 15% to 40% of those with prolonged HBV infection will develop cirrhosis, liver failure, hepatocellular carcinoma (HCC), or early death. According to the Global Burden of Disease study in 2013, HBV is responsible for up to 700,000 deaths annually, making it together with hepatitis C virus (HCV) infection the seventh leading cause of mortality globally.

Progression of chronic hepatitis B (CHB) to cirrhosis and HCC is determined by host-related factors like sex, as well as by viral and other factors (e.g., alcohol use). However, a factor that has had less attention in scientific research is the influence of ethnicity on disease outcome. Furthermore, for HCV, ethnicity is an essential predictor of disease outcome. For instance, more advanced hepatic fibrosis in Hispanics compared to non-Hispanic whites was related to older age and higher occurrence of hepatic steatosis. In addition, studies determining the natural history of HCV have observed less cirrhosis in African Americans when compared with other groups. However, in contrast to HCV, there is little known about the influence of ethnicity on the outcome of HBV infection.

The impact of migration in the European Union (EU) is striking as a high proportion of newly diagnosed CHB infections are considered to have been acquired outside the EU. Migration to the EU occurs mainly from countries with high prevalence of viral hepatitis B. Therefore this study was designed to assess whether foreign-born CHB patients have more advanced fibrotic liver disease than Dutch- or Belgian-born patients, with a main focus on the Turkish population that is disproportionately affected by HBV and is a key risk group for CHB in different EU countries.

2 | PATIENTS AND METHODS

CHB patients, defined as those with more than 6 months hepatitis B surface antigen positivity, who were still under follow-up between December 2009 and January 2015 at the hepatology outpatient department of three large educational hospitals, one in the Netherlands, one in Belgium, and one in the Northern Region of Turkey, were invited to participate in this study. Upon informed consent, missing data regarding socioeconomic status (SES), country of birth, mother’s country of birth, risk factors for HBV infection (intravenous drug use [IDU], blood transfusion before 1974, dialysis, healthcare worker, sex worker, men who sex with men [MSM], infected family member), alcohol abuse, and smoking were collected by a questionnaire. Alcohol abuse was defined as having more than two units per day for women and more than three units per day for men. Smoking was recorded as yes or no. In the current study, SES was based on income and education as follows: Low/Middle/High (L/M/H):

L: net income beneath poverty line based on EU-SILC 2012 / TÜRK-İŞ May 2014 without a degree of higher education.

M: net income beneath poverty line with a degree of higher education or a net income above poverty line without a degree of higher education.

H: net income above poverty line with a degree of higher education.

Relevant biological characteristics of HBV were also extracted from computerized laboratory records. The stage of fibrosis was classified according to METAVIR classification and assessed by liver biopsy and/or transient elastography. The development of cirrhosis was defined as a clinical syndrome consisting of either (1) histological confirmation of cirrhosis or (2) ultrasonographic findings of cirrhosis (included liver surface, edge, echotexture, echogenicity, diameter of main portal vein and splenic vein, outline of hepatic veins, and liver and spleen size) and/or clinical signs of advanced liver disease such as esophageal or gastric varices, ascites, spontaneous bacterial peritonitis (SBP), or hepatic encephalopathy. Medical record verification of all HCC diagnoses was based on the following criteria: a histopathological examination or a positive lesion detected by at least two different imaging techniques (e.g., computerized tomography, magnetic resonance imaging, transarterial chemoembolization, and dynamic contrast-enhanced ultrasonography with carbon dioxide).

The main focus of this study was to assess the disease outcome of CHB in the foreign-born patients compared to the Dutch- or Belgian-born patients. In a subanalysis, a comparison was made between Turkish immigrants, that is, patients living in the Netherlands or Belgium, and Turkish locals, that is, patients living in Turkey.

The ethnic groups have been compared regarding baseline characteristics (e.g., mean age, sex, and SES), biological characteristics (e.g., baseline hepatitis B e antigen [HBeAg] status, baseline alanine aminotransferase level), and disease outcome (e.g., hepatic fibrosis, and cirrhosis). Baseline was defined as time of CHB diagnosis.

The Medical Research Ethics Committee Maastricht (13-4-067), Ethical Committee of Ziekenhuis Oost-Limburg (14/095U), and Clinical Research Ethical Committee of Ondokuz Mayis University (B.30.2.ODM.0.20.08/1316) approved the study and the patients gave written informed consent.

2.1 | Statistical analysis

Anonymous data collection and analyses were performed using SPSS (Release 21; IBM, Armonk, NY). Categorical data were analysed with the \( \chi^2 \) test or Fisher’s exact test. In case, the observed value was zero a Laplace correction was applied, that is, adding one in all cells yielding a more honest test procedure. Differences in two continuous variables were assessed by the independent \( t \) test. The Kolmogorov-Smirnov test and Levene’s test were used to test whether a distribution was normal and for homogeneity of variance, respectively. When violating the assumptions for parametric tests, the Mann-Whitney test was used instead for comparing two continuous variables. Stepwise multiple logistic regression analysis was performed to determine independent predictors of cirrhosis. Results are presented as either with frequencies (%) or mean.
RESULTS

3.1 Baseline characteristics of the study population

Out of 1358 CHB patients, 269 participated in the study and provided additional information. Of the 269 CHB patients, 210 (78%) were foreign-born and 59 (22%) were Dutch- or Belgian-born. The foreign-born patients came from 35 different countries including 128 from Turkey (61%), 18 from China (9%), 5 from Morocco (2%), 5 from Italy (2%), 5 from Afghanistan (2%), and 5 from Indonesia (2%). With a focus on the Turkish population, a distinction was made between patients living in Turkey (local, n = 102) and Turkish CHB patients living in the Netherlands or Belgium (immigrant, n = 38). Figure 1 illustrates the flowchart of the study.

The baseline characteristics of the foreign-born group and Dutch- or Belgian-born group are presented in Table 1. The percentage of CHB patients with a low SES (58% vs 31%; P < 0.001) and an infected family member (47% vs 29%; P = 0.011) was higher in foreign-born patients compared with the Dutch- or Belgian-born group. However, in comparison to CHB patients born in the Netherlands or Belgium, there was a lower percentage of foreign-born patients with IDU (3% vs 10%; P = 0.027), MSM (1% vs 15%; P < 0.001), and alcohol abuse (3% vs 12%; P = 0.017).

Among the Turkish population, the percentage of CHB patients with a low SES (73% vs 61%; P = 0.170) and alcohol abuse (1% vs 5%; P = 0.120) was not different between local Turkish CHB patients and immigrant Turkish CHB patients. With regard to risk factors, there was no difference in the number of infected family members (46% vs 53%; P = 0.490).

3.2 Biological characteristics of the study population

When the patients were categorized according to the country of birth, a lower anti-human immunodeficiency virus positivity (3% vs 13%; P = 0.014) was seen in foreign-born group compared to Dutch- or Belgian-born group (Table 2). Among the Turkish population, there were no significant differences regarding anti-HCV positivity (4% vs 0%; P = 0.344), anti-HIV positivity (0% vs 0%), anti-HDV positivity (1% vs 6%; P = 0.297), and HBeAg positivity (13% vs 26%; P = 0.052) between local Turkish CHB patients and immigrant CHB patients.

3.3 HBV disease outcome

The HBV disease outcome in the ethnic groups is shown in Table 3. The foreign-born group had a significantly higher mean METAVIR fibrosis stage (1.9 ± 0.1) than the Dutch- or Belgian-born group (1.2 ± 0.2), P = 0.003. The prevalence of cirrhosis was 27% (foreign-born) and 10% (Dutch- or Belgian-born), P = 0.007. There was a trend of a higher prevalence of hepatic decompensation (P = 0.175) and HCC (P = 0.027) in the foreign-born group.
Among the Turkish population, a comparison was made between local Turkish CHB patients and immigrant Turkish CHB patients. In comparison to immigrant Turkish CHB patients, there was a comparable mean METAVIR fibrosis stage (2.3 ± 0.2 vs 2.0 ± 0.2; \( P = 0.334 \)), prevalence of cirrhosis (37% vs 27%; \( P = 0.262 \)), hepatic decompensation (16% vs 11%; \( P = 0.469 \)), and HCC (12% vs 3%; \( P = 0.115 \)).

A forward stepwise multiple logistic regression analysis of cirrhosis was then performed including all variables that had a \( P < 0.20 \) on univariate analysis (Table 4). The following variables were identified to be independent predictors of cirrhosis: low SES (odds ratio [OR], 5.7; 95% confidence interval [CI], 2.3-14.5; \( P < 0.001 \)) and baseline bilirubin levels (OR, 1.1; 95% CI, 1.0-1.1; \( P = 0.001 \)).

### TABLE 1 Baseline characteristics of 269 CHB patients according to foreign-born and Dutch- or Belgian-born

| Characteristics          | Foreign-born, \( n = 210 \) | Dutch- or Belgian-born, \( n = 59 \) | \( P \) |
|--------------------------|-----------------------------|-------------------------------------|-------|
| Age, y                   | 47 ± 0.9                    | 46 ± 2.0                            | 0.707 |
| Males                    | 117 (56)                    | 43 (73)                             | 0.018 |
| SES                      |                             |                                     |       |
| Low                      | 118 (58)                    | 15 (31)                             | 0.001 |
| Middle                   | 61 (30)                     | 22 (46)                             | 0.039 |
| High                     | 22 (11)                     | 10 (17)                             | <0.001|
| Risk factors             |                             |                                     |       |
| IDU                      | 6 (3)                       | 6 (10)                              | 0.027 |
| MSM                      | 1 (1)                       | 9 (15)                              | <0.001|
| Infected family member   | 99 (47)                     | 17 (29)                             | 0.011 |
| Other                    | 101 (48)                    | 1 (2)                               | <0.001|
| None                     | 3 (1)                       | 26 (44)                             | <0.001|
| Alcohol abuse            | 7 (3)                       | 7 (12)                              | 0.017 |
| Smoking                  | 46 (22)                     | 15 (25)                             | 0.568 |

Abbreviations: CHB, chronic hepatitis B; IDU, intravenous drug use; MSM, men who have sex with men; SEM, standard error of mean; SES, socioeconomic status. Values shown as mean ± SEM or as \( n \) (%).

Among the Turkish population, a comparison was made between local Turkish CHB patients and immigrant Turkish CHB patients. In comparison to immigrant Turkish CHB patients, there was a comparable mean METAVIR fibrosis stage (2.3 ± 0.2 vs 2.0 ± 0.2; \( P = 0.334 \)), prevalence of cirrhosis (37% vs 27%; \( P = 0.262 \)), hepatic decompensation (16% vs 11%; \( P = 0.469 \)), and HCC (12% vs 3%; \( P = 0.115 \)).

A forward stepwise multiple logistic regression analysis of cirrhosis was then performed including all variables that had a \( P < 0.20 \) on univariate analysis (Table 4). The following variables were identified to be independent predictors of cirrhosis: low SES (odds ratio [OR], 5.7; 95% confidence interval [CI], 2.3-14.5; \( P < 0.001 \)) and baseline bilirubin levels (OR, 1.1; 95% CI, 1.0-1.1; \( P = 0.001 \)).

### TABLE 2 Laboratory characteristics of 269 CHB patients according to foreign-born and Dutch- or Belgian-born

| Characteristics            | Foreign-born, \( n = 210 \) | Dutch- or Belgian-born, \( n = 59 \) | \( P \) |
|---------------------------|-----------------------------|-------------------------------------|-------|
| Anti-HCV positivity       | 10 (5)                      | 5 (10)                              | 0.325 |
| Anti-HIV positivity       | 6 (3)                       | 7 (13)                              | 0.014 |
| Anti-HDV positivity       | 5 (3)                       | 1 (2)                               | 1.000 |
| Baseline HBeAg positive status | 32 (16)                  | 18 (32)                             | 0.008 |
| Baseline HBV DNA level, log copies/mLa | 3 ± 4.7            | 7 ± 6.0                             | 0.091 |
| Baseline ALAT level, U/La | 39 ± 48.0                   | 125 ± 81.0                          | 0.005 |
| Baseline albumin level, g/La | 43 ± 7.7                 | 42 ± 7.7                            | 0.520 |
| Baseline bilirubin level, µmol/La | 11 ± 9.7              | 16 ± 11.3                           | 0.367 |
| Baseline platelets level, 109/L | 201 ± 5.6               | 212 ± 9.7                           | 0.370 |

Abbreviations: ALAT, alanine aminotransferase; CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; HCV, hepatitis C virus; HDV, hepatitis delta virus; SEM, standard error of mean. Values shown as mean ± SEM or as \( n \) (%).

*Median ± interquartile range is shown instead of mean ± SEM as Mann–Whitney test was used for these variables.*

### DISCUSSION

The impact of migration to Western Europe is striking as migrants have become the majority of CHB patients in low endemic countries, such as the Netherlands and Belgium. The Turkish migrant population, one of the largest migrant groups in Western Europe, is also disproportionately affected by HBV and is a key risk group for CHB infections in different Western European countries.

As ethnicity is an essential predictor of disease outcome in some diseases, this study assessed whether foreign-born CHB patients have more advanced fibrotic liver disease than Dutch- or Belgian-born patients. The CHB populations in three hospitals, one in the Netherlands, one in Belgium, and one in Turkey, were chosen because it afforded us a chance to study the differences between local Turkish CHB patients and immigrant Turkish CHB patients in a subanalysis.

The most significant finding was that SES appeared to be more important than ethnicity in influencing disease outcome in CHB patients. Compared with Dutch- or Belgian-born patients, the foreign-born CHB patients were associated with more advanced HBV-related liver disease with 27% having cirrhosis. There was also a trend of higher prevalence of hepatic decompensation and HCC in the foreign-born group. However, ethnicity was not associated with cirrhosis when SES was included in the multivariate analysis.

Although we are not aware of any other study that has examined the effect of ethnicity on disease outcome in CHB patients, there is evidence of greater HCV disease progression among Hispanics compared with non-Hispanic whites. In addition, several studies have observed less HCV-associated cirrhosis in African Americans than other ethnic groups.
TABLE 3 Disease outcome of 269 CHB patients according to foreign-born and Dutch- or Belgian-born

| Characteristics       | Foreign-born, n = 210 | Dutch- or Belgian-born, n = 59 | P     |
|-----------------------|-----------------------|-------------------------------|-------|
| Fibrosis stage (METAVIR) | 1.9 ± 0.1             | 1.2 ± 0.2                     | 0.003 |
| Cirrhosis             | 57 (27)               | 6 (10)                        | 0.007 |
| Hepatic decompensation | 23 (11)               | 3 (5)                         | 0.175 |
| HCC                   | 16 (8)                | 0 (0)                         | 0.027 |

Abbreviations: HCC, hepatocellular carcinoma; SEM, standard error of mean.
Values shown as mean ± SEM or as n (%).

However, the investigators assessing the influence of ethnicity on HCV-related liver disease did not attempt to adjust ethnic groups for socioeconomic status to mitigate the confounding effects on minority groups of lower SES.23 Disparities in disease outcome can be attributed to host genetics and environmental factors.24-26 Additionally, patient-related factors including SES become important during long and difficult course of disease management. Lower socioeconomic status in the foreign-born group may explain the worse disease outcome in this group as early diagnosis requires an awareness about HBV infection and associated risk factors, while some knowledge about the natural history of HBV may contribute to follow-up adherence. Delays in disease detection may result in worsened health outcomes in infected people.27

In line with our findings, the study by Haworth et al28 reported excess mortality from cirrhosis and HCC among first generation migrants in England and Wales. Moreover, different studies showed a higher incidence of HCC in the Asian immigrant population.24-26 Hypothesized explanation for the difference in liver disease outcome in the migrant population included earlier viral infection. In our study, we found a higher prevalence of infected family member as risk factor in the foreign-born group. On the contrary, MSM and IDU as risk factors were more prevalent in the Dutch- or Belgian-born group. These findings may indicate an earlier viral hepatitis B infection by perinatal or childhood horizontal transmission in foreign-born patients compared to HBV transmission through IDU or high-risk sexual behavior in adult age in the Dutch or Belgian patients. The predominant routes of transmission vary according the endemic frequency of HBV infection. In areas with low HBV endemicity, such as the Netherlands and Belgium, IDU and unprotected sexual intercourse in adults are the main routes of transmission, whereas in areas with high HBV endemicity, perinatal transmission is the predominant route.29-31 Childhood horizontal transmission is accepted as the most common route in in intermediate HBV endemic areas, such as Turkey.32 It has furthermore been accepted that horizontal transmission in early childhood may correlate with poor socioeconomic and hygienic conditions.33,34

In a subanalysis among the Turkish population, there was no difference in mean fibrosis stage, cirrhosis, hepatic decompensation, and HCC between local Turkish CHB patients and immigrant Turkish CHB patients. Factors affecting prognosis of CHB infection and cirrhosis, including alcohol abuse and coinfection (HCV, HIV, and HDV), were equally important among local Turkish CHB patients and among immigrant Turkish CHB patients and thus may explain the same prevalence of cirrhosis in both groups. According to the reported high number of infected family member of 46% and 53% in the local Turkish and in the immigrant Turkish CHB patients in our study, childhood horizontal transmission could be evenly important in both groups.

There are some limitations to the present study. First, this study has some selection bias toward the CHB population; those cured and deceased have not been included in this study, and there is also a possibility that there are CHB patients that have not yet visited the hepatology outpatient department. Second, the data must be interpreted carefully due to the small sample size of the study. Third, even though the patients’ income and highest education was recorded upon informed consent, the study by Karlsson et al23 explained the variability in conclusions of previous studies on the role of SES due to the fact that the income is an unstable measure of SES. However, in that study, 83% of the patients reported no change in income over the 42-month interval. Thus, we believe that changes in income status probably were not an important factor in our study. Fourth, participants may not have been 100% truthful with their answers to the questionnaires due to social desirability bias. Fifth, we cannot exclude the possibility that factors not included in this study might have a role in the examined

TABLE 4 Stepwise forward analysis for cirrhosis as outcome variable

| Factors significantly associated with cirrhosis on univariate analysis | P     |
|-------------------------------------------------------------|-------|
| Foreign-born group                                          | 0.007 |
| Low SES                                                     | <0.001|
| Middle SES                                                  | 0.001 |
| High SES                                                    | 0.009 |
| Anti-HCV positivity                                          | 0.058 |
| Baseline HBV DNA level                                      | 0.027 |
| Baseline ALAT level                                         | 0.040 |
| Baseline albumin level                                      | 0.023 |
| Baseline bilirubin level                                    | <0.001|

Values shown as mean ± SEM or as n (%).

Stepwise forward analysis

| Step 1                                      | B     | SE    | P     | 95% CI      |
|--------------------------------------------|-------|-------|-------|-------------|
| Baseline bilirubin level                   | 0.006 | 0.015 | 0.002 | 1.0-1.1     |
| Baseline albumin level                     | 0.010 | 0.007 | 0.001 | 1.0-1.1     |
| Baseline bilirubin level                   | 1.743 | 0.475 | 0.000 | 2.3-14.5    |

Abbreviations: ALAT, alanine aminotransferase; B, coefficient for the constant in the model; HCV, hepatitis C virus; SES, socioeconomic status; SE, standard error around the coefficient for the constant.

1Variables excluded in the forward stepwise analysis are: foreign-born group, middle SES, high SES, anti-HCV positivity, baseline HBV DNA level, baseline ALAT level and baseline albumin level.
worse disease outcome in foreign-born groups (eg, flares of hepatitis, HBV genotype, HBV variant, steatosis, diabetes, and obesity). HBV genotype varies according to ethnic backgrounds and there is growing evidence that the response to antiviral treatment and progression to cirrhosis and HCC differ according to HBV genotypes. However, since the determination of HBV genotype is not part of the standard procedure, information on genotype was not available to analyze their effect on disease outcome. Moreover, Fattovich et al showed that age, male sex, high levels of HBV replication, coinfection, and heavy alcohol consumption were the most important factors associated with increased risk of progression to cirrhosis. Each of these important factors were further incorporated in the current analysis.

In conclusion, these data suggest that SES and not ethnicity is likely to be associated with advanced fibrotic liver disease in patients with CHB. The finding of a similar prevalence of cirrhosis among local Turkish CHB patients and immigrant Turkish CHB patients is novel and warrants further investigation. Since the cultural diversity in Western Europe is growing, it is important to further assess the impact of ethnicity on a pandemic disease such as hepatitis B, whether this difference is biological, cultural or environmental, so that patient care can be improved. It would be recommended to conduct a large prospective cohort study in which the genotypes of all CHB patients are assessed and their biological parameters (including HDV) in combination with additional measurements like FibroScan and sonography are registered over a longer period of time. Next to quantitative research, we also highly advocate for qualitative research. Firstly to adequately assess ethnic background, SES, mode of transmission, and risk factors. Secondly to get an idea of the disease perception and perception of the received care and treatment of CHB patients to improve treatment and thus increase survival rates and quality of life.

CONFLICTS OF INTEREST
The authors declare that there are no conflicts of interest.

ORCID
Özgür M. Koc http://orcid.org/0000-0003-3678-5703

REFERENCES
1. World Health Organization. Hepatitis B. Geneva, Switzerland: World Health Organization; 2017. http://www.who.int/mediacentre/factsheets/fs204/en/
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, current and emerging prevention and control measures. J Viral Hepatitis. 2004;11(2):97-107.
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335-352.
4. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081-1088.
5. Biswas A, Panigrahi R, Pal M, et al. Shift in the hepatitis B virus genotype distribution in the last decade among the HBV carriers from eastern India: possible effects on the disease status and HBV epidemiology. J Med Virol. 2013;85(8):1340-1347.
6. Moura IF, Lopes EP, Alvarado-Mora MV, Pinho JR, Carrilho FJ. Phylogenetic analysis and subgenotypic distribution of the hepatitis B virus in Recife, Brazil. Infect Genet Evol. 2013;14:195-199.
7. Verma S, Bonacini M, Govindarajan S, Kanel G, Lindsay KL, Redeker A. More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol. 2006;101(8):1817-1823.
8. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol. 2002;97(3):700-706.
9. Sharma S, Carballo M, Feld JJ, Janssen HLA. Immigration and viral hepatitis. J Hepatol. 2015;63(2):515-522.
10. Eurostat Statistics Explained. People at risk of poverty or social exclusion. Luxembourg, Belgium: Eurostat your key to European statistics; 2015. http://ec.europa.eu/eurostat/statistics-explained/index.php/People_at_risk_of_poverty_or_social_exclusion
11. Van der Veen YJ, de Zwart O, Mackenbach J, Richardus JH. Cultural tailoring for the promotion of hepatitis B screening in Turkish Dutch: a protocol for a randomized controlled trial. BMC Public Health. 2010;10:674.
12. Kocak N, Hepgul S, Ozbayburtlu S, et al. Trends in major transfusion-transmissible infections among blood donors over 17 years in Istanbul, Turkey. J Int Med Res. 2004;32(6):671-675.
13. NHG-Werkgroep Virushepatitis en andere leveraandoeningen. NHGStandaard Virushepatitis en andere leveraandoeningen (derde herziening). Huisarts Wet. 2016;59(3):108-119.
14. Lelbach WK. Epidemiology of alcoholic liver disease. Prog Liver Dis. 1976;5:494-515.
15. O’Shea RS, Dasarathy S, McCullough AJ, Practice Guideline Committee of the American Association for the Study of Liver D, Practice Parameters Committee of the American College of G. Alcoholic liver disease. Hepatology. 2010;51(1):307-328.
16. Cundiff JM, Uchino BN, Smith TW, Birmingham W. Socioeconomic status and health: education and income are independent and joint predictors of ambulatory blood pressure. J Behav Med. 2015;38(1):9-16.
17. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403.
18. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20(Pt 1):15-20.
19. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007;56(7):968-973.
20. Agresti A. Categorical Data Analysis. 2nd ed. New Jersey: John Wiley & Sons Inc; 2002:710.
21. Chu JJ, Wormann T, Popp J, et al. Changing epidemiology of hepatitis B and migration—a comparison of six Northern and North-Western European countries. Eur J Pub Health. 2013;23(4):642-647.
22. Crosse K, Umeadi OG, Anania FA, et al. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol. 2004;2(6):463-468.
23. Karlson EW, Daltroy LH, Lew RA, et al. The independence and stability of socioeconomic predictors of morbidity in systemic lupus erythematosus. Arthritis Rheum. 1995;38(2):267-273.
24. Grulich A, McCredie M, Coates M. Cancer incidence in Asian migrants to New South Wales, Australia. Br J Cancer. 1995;71(2):400-408.
25. Wong R, Corley DA. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med. 2008;121(6):525-531.
26. McDermott S, Desmeules M, Lewis R, et al. Cancer incidence among Canadian immigrants, 1980-1998: results from a national cohort study. *J Immigr Minor Health*. 2011;13(1):15-26.

27. Shah HA, Abu-amara M. Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review. *Clin Gastroenterol Hepatol*. 2013;11(8):922-933.

28. Haworth EA, Soni Raleigh V, Balarajan R. Cirrhosis and primary liver cancer amongst first generation migrants in England and Wales. *Ethn Health*. 1999;4(1-2):93-99.

29. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. *JAMA*. 1990;263(9):1218-1222.

30. Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. *J Infect Dis*. 1982;146(2):198-204.

31. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. *World J Hepatol*. 2012;4(3):74-80.

32. Değertekin H, Güney G. Horizontal transmission of hepatitis B virus in Turkey. *Public Health*. 2008;122(12):1315-1317.

33. Doganci T, Uysal G, Kir T, Bakirtas A, Kuyucu N, Doganci L. Horizontal transmission of hepatitis B virus in children with chronic hepatitis B. *World J Gastroenterol*. 2005;11(3):418-420.

34. Zervou EK, Gatselis NK, Xanthi E, Ziciadis K, Georgiadou SP, Dalekos GN. Intrafamilial spread of hepatitis B virus infection in Greece. *Eur J Gastroenterol Hepatol*. 2005;17(9):911-915.

35. Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. *World J Gastroenterol*. 2014;20(18):5427-5434.

**How to cite this article:** Koc ÖM, Robaeys G, Yıldırım B, Posthouwer D, Hens N, Koek GH. The influence of ethnicity on disease outcome in patients with chronic hepatitis B infection. *J Med Virol*. 2019;91:623-629. [https://doi.org/10.1002/jmv.25353](https://doi.org/10.1002/jmv.25353)